Seminars in Nuclear Medicine
Volume 38, Issue 2 , Pages 105-113 , March 2008

Tumor Biology-Guided Radiotherapy Treatment Planning: Gross Tumor Volume Versus Functional Tumor Volume

  • Chandan Guha, MD, PhD

      Affiliations

    • Department Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
    • Corresponding Author InformationAddress reprint requests to Chandan Guha, MD, PhD, Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY 10467.
    • ,
  • Alan Alfieri, MS

      Affiliations

    • Department Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
    • ,
  • M. Donald Blaufox, MD, PhD

      Affiliations

    • Department of Nuclear Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
    • ,
  • Shalom Kalnicki, MD

      Affiliations

    • Department Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

References 

  1. Mah D, Chen CC. Image guidance in radiation oncology treatment planning: The role of technologies on the planning process. Semin Nucl Med. 2008;38:114–118
  2. Brunetti J, Caggiano A, Rosenbluth B, et al. Technical aspects of positron emission tomography/computed tomography fusion planning. Semin Nucl Med. 2008;38:129–136
  3. Bourland JD, Shaw EG. The evolving role of biological imaging in stereotactic radiosurgery. Technol Cancer Res Treat. 2003;2:135–239
  4. Kim MK, Ryu JS, Kim SB, et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer. 2007;43:1385–1391
  5. Klopp AH, Chang JY, Tucker SL, et al. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007;69:1405–1416
  6. Erasmus JJ, Macapinlac HA, Swisher SG. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer. 2007;110:2155–2168
  7. Podoloff DA, Macapinlac HA. PET and PET/CT in management of the lymphomas. Radiol Clin North Am. 2007;45:689–696vii
  8. Yang WT, Le-Petross HT, Macapinlac H, et al: Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat, in press
  9. Erasmus JJ, Munden RF, Truong MT, et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: A confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006;1:478–486
  10. Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400–419
  11. Je SK, Ahn MI, Park YH. Detection of a small lung cancer hidden in pneumoconiosis with progressive massive fibrosis using F-18 fluorodeoxyglucose PET/CT. Clin Nucl Med. 2007;32:247–248
  12. Kim SY, Lee SW, Nam SY, et al. The feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck. J Nucl Med. 2007;48:373–378
  13. Ahn PH, Garg MK. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med. 2008;38:141–148
  14. Macapinlac H. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med. 2008;38:137–140
  15. Schöder H, Ong SC. Fundamentals of molecular imaging: Rationale and applications with relevance for radiation oncology. Semin Nucl Med. 2008;38:119–128
  16. Langen KJ, Jarosch M, Muhlensiepen H, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol. 2003;30:501–508
  17. Jager PL, Vaalburg W, Pruimet J, et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–445
  18. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res. 2001;61:110–117
  19. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of [18]F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805–1814
  20. Vallabhajosula S, Kostakoglu L, Kothari PJ, et al. Pharmacokinetics and biodistribution of radiolabelled choline in human subjects: Comaprison of [11C]Choline and [18F]fluorocholine. J Label Compd Radiopharm. 2005;48:S281
  21. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C] choline. J Nucl Med. 1997;38:842–847
  22. Hara T, Kosaka N, Kishi H. Development of [18F]-Fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187–199
  23. Henriksen G, Herz M, Hauser A, et al. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC). Nucl Med Biol. 2004;31:851–858
  24. Yoshimoto M, Waki A, Obata A, et al. Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate. Nucl Med Nucl Med Biol. 2004;31:859–865
  25. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549–555
  26. Ponde DE, Oyama N, Dence CS, et al. [18F]-Fluoroacetate, an analogue of C-11 acetate for tumor imaging. J Nucl Med. 2003;44:296
  27. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–292
  28. Luxen A, Guillaume M, Melega WP, et al. Production of 6-[18F]fluoro-L-dopa and its metabolism in vivo—a critical review. Int J Rad Appl Instrum B. 1992;19:149–158
  29. Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71
  30. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: Detection with 18F DOPA whole body PET—initial results. Radiology. 2002;222:507–512
  31. Becherer A, Szabo M, Karanikas G, et al. Imaging of advanced neuroendocrine tumors with [18]F-FDOPA PET. J Nucl Med. 2004;45:1161–1167
  32. Inoue TJ, Tomiyoshi K, Higuchi T, et al. Biodistribution studies on L-3-[18F]fluoro-α-methyl tyrosine: A potential tumor-detecting agent. J Nucl Med. 1998;39:663–667
  33. Wilson I, Chatterjee S, Wolf W. The use of 3′-fluoro-3′-deoxythymidine and studies of its 18F-radiolabeling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS. ABST J Fluorine Chem. 1991;55:283–289
  34. Grierson JR, Shields AF. Radiosynthesis of 3′-Deoxy-3′-[18F]fluoro thymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143–156
  35. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin N Am. 2005;43:153–167
  36. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  37. Seitz U, Wagner M, Neumaier B, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[18F]fluoro-3′-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging. 2002;29:1174–1181
  38. Grierson JR, Schwartz JL, Muzi M, et al. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl Med Biol. 2004;31:829–837
  39. Shields AF. PET imaging with 18F-FLT and thymidine analogs: Promise and pitfalls. J Nucl Med. 2003;44:1432–1434
  40. Jerabeck PA, Patrick TB, Kilbourn MR, et al. Synthesis and biodistribution of 18F labeled fluoronitroimidazoles: Potential in vivo markers of hypoxic tissue. Int J Radiat Appl Instrum. 1986;37:599–605
  41. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987;111:292–304
  42. Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–5441
  43. Gronroos T, Eskola O, Lehtio K, et al. Pharmacokinetics of [18F]FETNIM: A potential marker for PET. J Nucl Med. 2001;42:1397–1404
  44. Rasey JS, Hofstrand PD, Chin LK, et al. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med. 1999;40:1072–1079
  45. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106–113
  46. Beck R, Roper B, Carlsen JM, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973–980
  47. Foo SS, Abbott DF, Lawrentschuk N, et al. Functional imaging of intra-tumoral hypoxia. Mol Imaging Biol. 2004;6:291–305
  48. Kiesewetter DO, Kilbourn MR, Landvatter SW, et al. Preparation of four fluorine-18 labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212–1221
  49. Lim JL, Zheng L, Berridge MS, et al. The use of 3-methoxymethyl-l6β, 17β-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-l 8-16α-fluoroestradiol. Nucl Med Biol. 1996;23:911–915
  50. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-fluoroestradiol (FES). Nucl Med Biol. 1997;24:341–348
  51. Ahmed N, Langlois R, Rodrigue S, et al. Automated synthesis of 11β-methoxy-4-16α-[16α-18F]difluoroestradiol (4F-M[18F]FES) for estrogen receptor imaging by positron emission tomography. Nucl Med Biol. 2007;34:459–464
  52. Seimbille Y, Ali H, van Lier JE. Synthesis of 2, 16α- and 4,16α difluoroestradiols and their 11β-methoxy derivatives as potential estrogen receptor-binding radiopharmaceuticals. J Chem Soc Perkin Trans. 2002;1:657–663
  53. Van de Wiele C, De Vos F, Slegers G, et al. Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: A review. Eur J Nucl Med. 2000;27:1421–1433
  54. Haseman MK, Rosenthal SA, Kipper SL, et al. Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer. Urology. 2007;70:303–308
  55. Mohammed AA, Shergill IS, Vandal MT, et al. ProstaScint and its role in the diagnosis of prostate cancer. Expert Rev Mol Diagn. 2007;7:345–349
  56. Lacy GL, Soderdahl DW, Hernandez J. Optimal cost-effective staging evaluations in prostate cancer. Curr Urol Rep. 2007;8:190–196
  57. Choi JY, Jang KT, Shim YM, et al. Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: Comparison with positron emission tomography. Ann Surg Oncol. 2006;13:1054–1062
  58. Beer AJ, Hauber R, Sarbia M, et al. PET using 18Fgalacto-RGD identifies the level of integrin alphavbeta3 expression in man. Clin Can Res. 2006;12:3942–3949
  59. Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the alphavbeta3 selective tracer 18F Galacto-RGD in cancer patients. J Nuc Med. 2005;46:1333–1341
  60. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease with 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–278
  61. Blake GM, Park-Holohan SJ, Cook GJ, et al. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49
  62. Hamaoka J, Madewell E, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–2953
  63. Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nuclear Med. 1999;40:184–191
  64. Shulkin BL, Hutchinson RJ, Castle VP, et al. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743–750
  65. Mortimer JE, Dehdashti F, Siegel BA, et al. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose with 16α-[18F] fluoro-17β-oestradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933–939
  66. Winnard P, Raman V. Real time non-invasive imaging of receptor-ligand interactions in vivo. J. Cellular Biochem. 2003;90:454–463
  67. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948–1958
  68. Wester H-J. Nuclear imaging probes: From bench to bedside. Clin Cancer Res. 2007;13:3470–3481
  69. Gupta N, Price PM, Aboagye EO. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer. 2002;38:2094–2107
  70. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods. Cancer Res. 2005;65:10104–10112
  71. Pnwar P, Iznaga-Escobar N, Mishra P, et al. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther. 2005;4:854–860
  72. Kang KW, Min JJ, Chen X, et al. Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture. Mol Imaging Biol. 2005;7:296–303
  73. Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65:1471–1478
  74. Zanzonico PB, Finn R, Pentlow KS, et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med. 2004;45:1966–1971
  75. Choi SJ, Kim JS, Kim JH, et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653–659
  76. Juhasz C, Chugani DC, Muzik O, et al. In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors. J Cereb Blood Flow Metab. 2006;26:345–357
  77. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: Positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102:318–327
  78. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678–687
  79. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:422–429
  80. Shulkin BL, Wieland DM, Baro ME, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37:16–21
  81. Shulkin BL, Wieland DM, Castle VP, et al. Carbon-11 epinephrine PET imaging of neuroblastoma. J Nucl Med. 1999;40:129P
  82. Franzius C, Hermann K, Weckesser M, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic system: Feasibility study and comparison with 123I-MIBG SPECT-CT. J Nucl Med. 2006;47:1635–1642
  83. Brink I, Schaefer O, Walz M, et al. Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med. 2006;31:39–41
  84. Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med. 1995;36:644–650
  85. Carroll VA, Glaser M, Aboagye E, et al. Imaging vascular endothelial growth factor in vivo with positron emission tomography. Br J Cancer. 2000;83:P6
  86. Blasberg RG, Roelcke U, Weinreich R, et al. Imaging brain tumour proliferative activity with [124I]iododeoxyuridine. Cancer Res. 2000;60:624–635
  87. Dimitrakopoulou A, Strauss LG, Clorius JH, et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med. 1993;34:1075–1081
  88. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997;17:1573–1576
  89. de Groot TJ, Verhagen A, Elsinga PH, et al. Synthesis of [18F]fluoro-labeled progestins for PET. Int J Rad Appl Instrum [A]. 1991;42:471–474
  90. Liu A, Carlson KE, Katzenellenbogen JA. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor (Potential agents for imaging prostatic cancer by positron emission tomography). J Med Chem. 1992;35:2113–2129
  91. Liu A, Dence CS, Welch MJ, et al. Fluorine-18-labelled androgens: Radiochemical synthesis and tissue distribution and studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med. 1992;33:724–734
  92. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349–6354
  93. Aboagye EO, Kelson AB, Tracy M, et al. Preclinical development and current status of the fluorinated 2- nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2- nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17):a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anticancer Drug Des. 1998;13:703–730
  94. Lemmer K, Ahnert-Hilger G, Hopjner M, et al. Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci. 2002;71:667–678
  95. Raderer M, Kurtaran A, Leimer M, et al. Value of peptide receptor scintigraphy using 123I-vasoactive intestinal peptide and 111In-DTPA-d-Phe1-octreotide in 194 carcinoid patients: Vienna University experience, 1993 to 1998. J Clin Oncol. 2000;18:1331–1336
  96. Satyamurthy N, Bida GT, Barrio JR, et al. No-carrier-added 3-(2′-[18F]fluoroethylspiperone, a new dopamine receptor-binding tracer for positron emission tomography. Nucl Med Biol. 1986;13:617–624
  97. Ugur O, Kothari PJ, Finn RD, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29:147–157
  98. Vaidyanathan G, Zalutsky MR. Fluorine-18-labeled [Nle4, D-Phe7]-α -MSH, an α-melanocyte stimulating hormone analogue. Nucl Med Biol. 1997;24:171–178
  99. Wu AM, Williams LE, Zieran L, et al. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Target. 1999;4:47–58
  100. Wu AM, Yazaki PJ, Tsai SW, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA. 2000;97:8495–8500
  101. Shaul M, Abourbeh G, Jacobson O, et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem. 2004;12:3421–3429
  102. Mishani E, Abourbeh G, Jacobson O, et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem. 2005;48:5337–5348
  103. Rajendran JG, Mankoff DA. Beyond detection: Novel applications for PET imaging to guide cancer therapy. J Nucl Med. 2007;48:855–856
  104. Rosenberg SA. Progress In human tumour Immunology and Immunotherapy. Nature. 2001;411:380–384
  105. Bigbee W, Herberman RB. Tumor markers and immunodiagnosis. In:  Kufe DW,  Pollock RE,  Weichselbaum RR, et al. editor. Cancer Medicine. (ed 6). Hamilton, ON, Canada: BC Decker; 2003;p. 209–220

PII: S0001-2998(07)00145-6

doi: 10.1053/j.semnuclmed.2007.12.001

Seminars in Nuclear Medicine
Volume 38, Issue 2 , Pages 105-113 , March 2008

Article Tools